Derek Abbott Takes Leadership of Immunology and Genomic Medicine at National Jewish Health

Derek Abbott Takes Leadership Role at National Jewish Health

In a notable development for the field of immunology, Derek Abbott, MD, PhD, has stepped into the role of Cecil and Ida Green Chair of the Department of Immunology and Genomic Medicine at National Jewish Health. This esteemed position, which Abbott commenced in July 2025 following a comprehensive national search, underscores the institution's dedication to advancing medical research and patient care.

Dr. Abbott joins National Jewish Health from Case Western Reserve University School of Medicine, where he held the role of Arline H. and Curtis Garvin Professor of Medicine in the Department of Pathology since 2006. His extensive career boasts significant contributions to both research and education, as well as leadership in various capacities. In his previous role, he was pivotal in directing the Medical Scientist Training Program at CWRU, ensuring the development of future leaders in the medical and scientific community.

Expressing his enthusiasm regarding this new chapter, Dr. Abbott remarked, “I am honored to take on this leadership role at National Jewish Health. I look forward to building on the department's legacy of discovery science and advancing research that improves the lives of patients worldwide.” His research uniquely merges the fields of genetics and immunology, focusing on the genetic underpinnings of inflammatory and autoimmune diseases. This expertise is expected to guide innovative drug development and enhance therapeutic strategies for patients.

Michael Salem, MD, the CEO and president of National Jewish Health, expressed confidence in Dr. Abbott's capabilities, stating, “Dr. Abbott is a highly respected researcher within the fields of immunology and genomic medicine. He brings tremendous experience, knowledge, and collaborative leadership, and we are excited to have him lead this key area of our institution.”

Dr. Abbott’s academic pedigree is impressive. He completed his undergraduate studies at the University of Virginia in 1993 and obtained his MD and PhD in Cell Biology from Vanderbilt University School of Medicine through the Medical Scientist Training Program. His subsequent training at Brigham and Women’s Hospital, affiliated with Harvard Medical School, further honed his focus on integrating genetics with immunology to uncover new therapeutic targets, a mission that he continues to pursue in his current research.

National Jewish Health has a remarkable history in medical innovation and patient care, being the only facility globally that is dedicated entirely to pioneering research and treatment for individuals facing respiratory, cardiac, immune, and related disorders. Situated in Denver, this institution draws patients from around the globe, offering cutting-edge and coordinated medical care.

As Dr. Abbott steps into his new role, he succeeds Philippa Marrack, PhD, FRS, a prominent immunologist whose leadership over the last 15 years has left an indelible mark on the department. Recognized for her groundbreaking discoveries, Dr. Marrack has greatly influenced the field of immune-based therapies, leading to transformative treatment options for various conditions, including cancer and autoimmune diseases. Her accolades are numerous, including induction into the National Women's Hall of Fame and the Colorado Women's Hall of Fame, alongside her 2015 Wolf Prize in Medicine.

In acknowledgment of Dr. Marrack’s exceptional contributions, Dr. Salem stated, “We are deeply grateful for Dr. Marrack's lasting impact in the field of medicine and for our organization. Her career, spanning more than 50 years, has impacted lives throughout the world, as well as those of us who have had the privilege to work with and learn from her.”

Looking ahead, National Jewish Health aims to further solidify its position as a leader in medical science, propelled by Dr. Abbott’s expertise and vision. As immunology continues to play a critical role in understanding and treating complex diseases, the leadership transition at National Jewish Health is both timely and promising for advancements in patient care and scientific discovery.